Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Alicia K.  Morgans

Alicia K. Morgans, M.D.

Assistant Professor of Medicine
Medical Oncologist

  • Appointments
    (615) 936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    (615) 322-4967

    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    (615) 322-4967
  • Faxes
    Division of Hematology/Oncology Fax
    (615) 343-7602
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    (615) 343-7602
    Clinic Fax
    (615) 343-8668
  • Addresses
    Clinic
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, TN 37232-7415

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
    Website

    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    Vanderbilt-Ingram Cancer Center
    2220 Pierce Ave.
    777 Preston Research Building
    Nashville, TN 37232
Profile

Dr. Morgans is an Assistant Professor of Medicine in the Division of Hematology/Oncology. She specializes in the treatment of genitourinary malignancies, including cancers of the prostate, bladder, testis (germ cell) and penis. She received a bachelor's degree with honors in biology before going to medical school at the University of Pennsylvania School of Medicine.
Read more...

Dr. Morgans is an Assistant Professor of Medicine in the Division of Hematology/Oncology. She specializes in the treatment of genitourinary malignancies, including cancers of the prostate, bladder, testis (germ cell) and penis. She received a bachelor's degree with honors in biology before going to medical school at the University of Pennsylvania School of Medicine. She then went on to complete a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Morgans completed a fellowship in Hematology/Oncology at Harvard's Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston, before moving to Nashville as an Assistant Professor in Medicine.

Dr. Morgans is a specialist in genitourinary malignancies, with special interest in advanced prostate cancer. Her research investigates the side effects of cancer treatment (including the prevention, diagnosis of, and treatment of these effects) and treatment decision-making among men with advanced prostate cancer. She also has an interest in supporting clinical research of novel treatments for genitourinary malignancies. Dr. Morgans is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group.

Education
  • M.D., University of Pennsylvania School of Medicine, 2006
  • Residency, Internal Medicine, Hospital of the University of Pennsylvania, 2009
  • Fellowship, Dana Farber/Harvard Cancer Center/Massachusetts General Hospital, 2012
Publications
  • Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. Eur. Urol [print-electronic]. 2015 Jun; 67(6): 1019-25. PMID: 25174325, PMCID: PMC4412750, PII: S0302-2838(14)00788-X, DOI: 10.1016/j.eururo.2014.08.035, ISSN: 1873-7560.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25174325.
  • Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25649350.
  • Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA, Penson DF. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J. Urol [print-electronic]. 2015 Apr; 193(4): 1226-31. PMID: 25451829, PMCID: PMC4542148, PII: S0022-5347(14)04835-6, DOI: 10.1016/j.juro.2014.11.006, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25451829.
  • Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, Morgans AK, Penson DF. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J. Clin. Oncol [print-electronic]. 2015 Mar 3/20/2015; 33(9): 1078-85. PMID: 25667275, PII: JCO.2014.60.2557, DOI: 10.1200/JCO.2014.60.2557, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25667275.
  • Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Penson DF. Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis [print-electronic]. 2014 Dec; 17(4): 338-42. PMID: 25134939, PMCID: PMC4227957, PII: pcan201431, DOI: 10.1038/pcan.2014.31, ISSN: 1476-5608.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25134939.
  • Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, Penson DF, Resnick MJ, Smith JA, Clark PE. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int [print-electronic]. 2014 Oct 10/13/2014; PMID: 25307281, DOI: 10.1111/bju.12950, ISSN: 1464-410X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25307281.
  • Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer [print-electronic]. 2014 Apr 4/15/2014; 120(8): 1263-71. PMID: 24510400, DOI: 10.1002/cncr.28563, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24510400.
  • Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013 Jul; 2(4): 445-60. PMID: 24236685, DOI: 10.2217/cer.13.34, ISSN: 2042-6313.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24236685.
  • Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol. Clin. North Am [print-electronic]. 2012 Nov; 39(4): 533-46. PMID: 23084529, PMCID: PMC3721069, PII: S0094-0143(12)00057-2, DOI: 10.1016/j.ucl.2012.07.009, ISSN: 1558-318X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23084529.